On April 26, 2022 BioEclipse Therapeutics (BioEclipse), a privately held, clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, reported it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors (Press release, BioEclipse Therapeutics, APR 26, 2022, View Source;utm_medium=rss&utm_campaign=bioeclipse-therapeutics-awarded-almost-8-million-grant-by-california-institute-for-regenerative-medicine-cirm-to-fund-ongoing-phase-1-crx100-cancer-immunotherapy-clinical-trial [SID1234613503]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BioEclipse is performing a Phase 1 clinical study evaluating the safety and tolerability of CRX100, a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells. These immune cells naturally locate and destroy cancer cells and when combined with our oncolytic virus create a powerful cancer immunotherapy to treat patients who are resistant to standard of care treatments and have recurring disease.
BioEclipse President and CEO Pamela Reilly Contag, Ph.D. and Principal Investigator of the grant, said, "We believe the best way to cure cancer is by developing new, multi-mechanistic therapies that are safe, effective, and accessible to diverse populations. Our technology harnesses two distinct methods of action using immune cells loaded with a cancer-killing virus that targets cancer tissue but spares healthy tissue. Immunotherapies such as CRX100 are an extremely powerful approach to give oncologists another tool to improve outcomes, while giving the body tools to fight a relapse and recurrence. We extend our sincerest appreciation to CIRM. Their support has validated our technology and expertise, and we welcome opportunities with partners and investors moving forward as we work towards achieving our goals."
Oliver Dorigo, M.D., Ph.D., Principal Investigator of the clinical trial and Director of the Gynecologic Cancer Service at Stanford University, said, "CRX100 addresses a significant unmet medical need in fatal conditions for which there are limited treatment options. CRX100, which migrates to the tumor site, targets tumor cells and delivers the cancer-destroying virus, has the potential to significantly help those with chemotherapy-resistant or refractory solid tumors—including colorectal cancer, triple-negative breast cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, and osteosarcoma." The trial locations also include HonorHealth Research Institute in Scottsdale, Arizona, and UC San Diego Moores Cancer Center in La Jolla, California.